期刊论文详细信息
European Medical Journal Hematology
Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis
article
Ajay Kakkar1  Gary Raskob2  Mari Thomas3  Paula Bolton-Maggs4  Giancarlo Agnelli6 
[1] Thrombosis Research Institute;University of Oklahoma Health Sciences Center;University College London;University of Manchester;UK Haemovigilance Scheme;University of Perugia;Istituti Clinici Scientifici
DOI  :  10.33590/emj/10175843
来源: European Medical Journal
PDF
【 摘 要 】

This symposium took place during the International Society on Thrombosis and Haemostasis (ISTH) Congress, 2022. Ajay Kakkar, Thrombosis Research Institute, London, UK, opened the symposium by highlighting the extent to which patients with cancer are affected by thrombotic disease. Subsequently, Mari Thomas, University College London, UK, described the current treatment options for patients with cancer-associated thrombosis (CAT). Thomas highlighted the current unmet needs faced by these patients, with the risk of bleeding continuing to be the main issue affecting anticoagulation treatment. Paula Bolton-Maggs, University of Manchester, UK, and UK Haemovigilance Scheme, Manchester, UK, gave an overview of Factor XI (FXI) inhibition and outlined why this factor is a potential attractive anticoagulation drug target. Multiple therapies targeting FXI are currently in development, with seven clinical trials published to date. 1-7 Although there are some similarities between these agents, there are also many differences in terms of their administration route and frequency, the timing of onset of action, and methods of metabolism and excretion. Giancarlo Agnelli, University of Perugia, Italy, and Istituti Clinici Scientifici (ICS) Maugeri, Pavia-Milan, Italy, then described the importance of conducting clinical trials that are designed to address the unmet needs of patients with CAT. In particular, he highlighted the ongoing Phase III ASTER and MAGNOLIA studies that are aiming to demonstrate that the FXI inhibitor abelacimab is superior to standard of care treatments in terms of bleeding rates for patients with CAT, including those with gastrointestinal (GI) or genitourinary (GU) tumours. Concluding remarks were given by Gary Raskob, University of Oklahoma Health Sciences Center, Oklahoma City, USA, who re-emphasised the unmet needs in the treatment of CAT, and the promise that FXI inhibitors hold for the future.

【 授权许可】

CC BY-NC   

【 预 览 】
附件列表
Files Size Format View
RO202302050000130ZK.pdf 923KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:0次